Results 141 to 150 of about 7,362 (230)

Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization. [PDF]

Int J Mol Sci
González-Pico L, Camino T, Ortigueira S, Prieto-Díaz R, Sotelo E, Majellaro M.   +5 more
europepmc   +1 more source

Computational strategies to address therapeutic resistance in estrogen receptor‐positive breast cancer: A narrative review of molecular docking, molecular dynamics simulations, and emerging therapeutic targets

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
Computational drug discovery integrates molecular docking, molecular dynamics simulations, and translational clinical targeting to identify next‐generation therapeutics that overcome endocrine resistance in ER‐positive breast cancer. Combined with multi‐omics, artificial intelligence, and biomarker‐guided precision oncology, these approaches accelerate
Emmanuel Ifeanyi Obeagu, Yaregal Asres
wiley   +1 more source

Induced proximity-based therapeutics for advanced prostate cancer. [PDF]

NPJ Drug Discov
Ching J, Chau CH, Figg WD.
europepmc   +1 more source

Targeting the PI3K/Akt Signaling Pathway: A Promising Therapeutic Strategy to Reduce Cancer Mortality and Overcome Chemoresistance

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aims The phosphatidylinositol 3‐kinase (PI3K)/Akt signaling pathway is a central regulator of cellular properties that are essential for cancer progression, including cellular growth, survival, metabolism, and angiogenesis. Dysregulated PI3K/Akt signaling, often caused by genetic alterations in PIK3CA, loss of PTEN, or the ...
Md Mohiuddin
wiley   +1 more source

Understanding the Potential of Antibody‐Drug Conjugates Functionalized Engineered Exosomes in Hepatocellular Carcinoma Therapy: A Comprehensive Narrative Review

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Exosomes are naturally secreted nanovesicles with high biocompatibility, low immunogenicity, and the ability to traverse biological barriers, making them attractive theragnostic carriers. When engineered to present tumor‐specific antibodies and to deliver antibody‐drug conjugates (ADCs), they may enhance selective targeting of ...
Subham Sarkar, Avinaba Bose, Jenifer Rajak, Arup Kumar Mitra, Ajoy Kumer, Bikram Dhara   +5 more
wiley   +1 more source

Dual PROTACs Versus Dual Inhibitors in Oncology: A Medicinal Chemistry and Linker Design Perspective. [PDF]

Pharmaceuticals (Basel)
Bisi N, Hamze A.
europepmc   +1 more source

Sigma‐1 Receptor‐Targeting Compounds Show Antiviral Activity Across Multiple Coronavirus Models

Journal of Medical Virology, Volume 98, Issue 10, October 2026.
ABSTRACT Over the past two decades, coronaviruses have caused three major public health crises, including the epidemics of SARS‐CoV, MERS‐CoV, and SARS‐CoV‐2. Following the outbreak of SARS‐CoV‐2, several antiviral drugs have been approved for the treatment of COVID‐19.
Cuiling Zhang, Xingpeng Dong, Jiaying Liu, Minghua chen, Lisen Lin, Gaojie Song, Xianzhu Xia, Gaoxing Su, Xiao Li, Chao Shang   +9 more
wiley   +1 more source

4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling. [PDF]

Drug Dev Res
Wang Q, Huang Q, Ou H, Huang T, He Y, Li P.   +5 more
europepmc   +1 more source

Posttranslational Modifications of p62/SQSTM1 in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Schematic illustration of p62 as a posttranslational modifications (PTMs)‐programmed integrator in homeostasis, pathogenesis, and therapeutic targeting. (Left) Homeostasis: In physiological states, p62, through various PTMs such as phosphorylation, ubiquitination, and acetylation, coordinates essential cellular functions.
Weikai Wang, Xin Jiang, Runing Qiu, Chandra Sugiarto Wijaya, Miaoqin Chen, Jin Wang, Liyuan Zhu, Hongchuan Jin, Lifeng Feng   +8 more
wiley   +1 more source

Delivering Degradation: Nanomedicine and Programmable Proximity Platforms for Targeted Protein Degradation. [PDF]

Pharmaceutics
Amin A, Nawaz T, Oliveira Ferreira O, Santana de Oliveira M.   +3 more
europepmc   +1 more source